Literature DB >> 10751332

Cellular mechanisms involved in carotid body inhibition produced by atrial natriuretic peptide.

L He1, B Dinger, S Fidone.   

Abstract

Atrial natriuretic peptide (ANP) and its analog, atriopeptin III (APIII), inhibit carotid body chemoreceptor nerve activity evoked by hypoxia. In the present study, we have examined the hypothesis that the inhibitory effects of ANP and APIII are mediated by cyclic GMP and protein kinase G (PKG) via the phosphorylation and/or dephosphorylation of K(+) and Ca(2+) channel proteins that are involved in regulating the response of carotid body chemosensory type I cells to low-O(2) stimuli. In freshly dissociated rabbit type I cells, we examined the effects of a PKG inhibitor, KT-5823, and an inhibitor of protein phosphatase 2A (PP2A), okadaic acid (OA), on K(+) and Ca(2+) currents. We also investigated the effects of these specific inhibitors on intracellular Ca(2+) concentration and carotid sinus nerve (CSN) activity under normoxic and hypoxic conditions. Voltage-dependent K(+) currents were depressed by hypoxia, and this effect was significantly reduced by 100 nM APIII. The effect of APIII on this current was reversed in the presence of either 1 microM KT-5823 or 100 nM OA. Likewise, these drugs retarded the depression of voltage-gated Ca(2+) currents induced by APIII. Furthermore, APIII depressed hypoxia-evoked elevations of intracellular Ca(2+), an effect that was also reversed by OA and KT-5823. Finally, CSN activity evoked by hypoxia was decreased in the presence of 100 nM APIII, and was partially restored when APIII was presented along with 100 nM OA. These results suggest that ANP initiates a cascade of events involving PKG and PP2A, which culminates in the dephosphorylation of K(+) and Ca(2+) channel proteins in the chemosensory type I cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751332     DOI: 10.1152/ajpcell.2000.278.4.C845

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  Hypoxia regulates the natriuretic peptide system.

Authors:  Olli Arjamaa; Mikko Nikinmaa
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-07

2.  Ghrelin reduces voltage-gated potassium currents in GH3 cells via cyclic GMP pathways.

Authors:  Xue Feng Han; Yun Long Zhu; Maria Hernandez; Damien J Keating; Chen Chen
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

Review 3.  A chronic pain: inflammation-dependent chemoreceptor adaptation in rat carotid body.

Authors:  X Liu; L He; B Dinger; C Gonzalez; L Stensaas; S Fidone
Journal:  Respir Physiol Neurobiol       Date:  2011-03-17       Impact factor: 1.931

4.  ROS and cGMP signaling modulate persistent escape from hypoxia in Caenorhabditis elegans.

Authors:  Lina Zhao; Lorenz A Fenk; Lars Nilsson; Niko Paresh Amin-Wetzel; Nelson Javier Ramirez-Suarez; Mario de Bono; Changchun Chen
Journal:  PLoS Biol       Date:  2022-06-21       Impact factor: 9.593

5.  Sustained exposure to cytokines and hypoxia enhances excitability of oxygen-sensitive type I cells in rat carotid body: correlation with the expression of HIF-1α protein and adrenomedullin.

Authors:  Xuemei Liu; Liang He; Bruce Dinger; Larry Stensaas; Salvatore Fidone
Journal:  High Alt Med Biol       Date:  2013-03       Impact factor: 1.981

6.  Adaptation to chronic hypoxia involves immune cell invasion and increased expression of inflammatory cytokines in rat carotid body.

Authors:  X Liu; L He; L Stensaas; B Dinger; S Fidone
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-31       Impact factor: 5.464

7.  GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition.

Authors:  Audrys G Pauza; Pratik Thakkar; Tatjana Tasic; Igor Felippe; Paul Bishop; Michael P Greenwood; Kristina Rysevaite-Kyguoliene; Julia Ast; Johannes Broichhagen; David J Hodson; Helio C Salgado; Dainius H Pauza; Nina Japundzic-Zigon; Julian F R Paton; David Murphy
Journal:  Circ Res       Date:  2022-02-01       Impact factor: 17.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.